Navigation Links
Ex-IITian-designed Alzheimer's Drug's Human Clinical Trials Begin

Purdue University researchers have begun the first phase of human clinical trials to test the efficacy of an Alzheimer's drug designed in-house.

The drug is based on an inhibitor developed by a team of researchers at the university. The researchers say that it may help intercept and disable the disease at an early stage.

"Millions of people suffer from this devastating disease and treatment options are very limited," said Professor Arun Ghosh, who led the creation of the treatment molecule.

"Current drugs manage the symptoms, but this could be the first disease-modifying therapy. It may be able to prevent and reverse the disease," Ghosh, who did his MSc from MSc, Indian Institute of Technology, Kanpur in 1981.

CoMentis Inc., a San Francisco-based biopharmaceutical firm co-founded by Professor Ghosh and Oklahoma Medical Research Foundation (OMRF) scientist Jordan Tang, is initiating the clinical trials of the experimental drug CTS-21166.

The trial, which comprises of 48 healthy volunteers, will measure safety, tolerability, and pharmacokinetics of CTS-21166 at various doses.

Its results are expected to be out by the end of 2007, and the researchers expect to begin phase II studies in Alzheimer's patients in 2008.

In 2000, Professor Ghosh had built an inhibitor that had the ability to bind to and inactivate the beta-secretase enzyme, which is significant to the progression of Alzheimer's. Since then he has been leading the structure-based design of these inhibitors for therapeutic intervention of the disease.

His most recent work, which led to the creation of beta-secretase inhibitor CTS-21166, was published in the Journal of Medicinal Chemistry.

"The molecule is both highly potent and highly selective, meaning it does not appear to affect other enzymes important to brain function or cause harmful side effects," Professor Ghosh said.

"It took years of work and evaluation of hundreds of molecules to achieve one with the strength and safety necessary for clinical potential," he added.


'"/>




Related medicine news :

1. Evidence Links Protein Damage to Neurodegenerative diseases like Parkinsons and Alzheimers
2. Decrease in testosterone levels lead to Alzheimers
3. Smokers are prone to Alzheimers
4. Over-The-Counter Drugs May Prevent Alzheimers
5. Alzheimers followed by head injury
6. Vitamin E useful for Alzheimers
7. Staying mentally energitic prevents Alzheimers
8. Researchers trick Alzheimers Enzyme
9. Drug Offers Hope for Alzheimers disease
10. Alzheimers with psychosis runs in families
11. Blood test may aid foretell Alzheimers
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/9/2016)... (PRWEB) , ... December 09, 2016 , ... An inventor ... amputees to safely ride all types of amusement park rides. , The patent-pending SAFETY ... unit is easy to use and could be set up in a matter of ...
(Date:12/9/2016)... ... December 09, 2016 , ... The ... Cable Network (PCN) during the summer of 2016. The program was made possible ... the United States Department of Health and Human Services Administration. The broadcast, ...
(Date:12/8/2016)... ... December 08, 2016 , ... ZyDoc , a ... and Conventional Data Capture Methods for Input to Electronic Health Records: A Comparative ... of the comparative usability study demonstrate that a dictation-based method (“NLP Entry”) using ...
(Date:12/8/2016)... ... December 08, 2016 , ... David J. Dykeman , ... Greenberg Traurig, LLP, will speak at DeviceTalks West, Dec. 12, 2016, at the Fairmont ... and attorneys from the firm’s global Life Sciences & Medical Technology Group have been ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... has been recognized for adherence to the highest standards of trauma, maternity, cancer ... announced the center's president and CEO, Dr. Daniel Messina. , Among the recognitions, ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... Research and Markets has announced the addition of the "Endodontic ... ... analyzes the worldwide markets for Endodontic Supplies in US$ Thousand. The report provides ... Japan , Europe , Asia-Pacific , ... estimates and forecasts are provided for the period 2015 through 2022. Also, a ...
(Date:12/8/2016)... Mederi Therapeutics Inc . anunciou aprovação regulatória, pela CFDA, e lançamento de ... refluxo gastroesofágico (DRGE). Foto -  http://photos.prnewswire.com/prnh/20161207/446903 ... ... procedure performed and broadcast during the Chinese Congress of Digestive Endoscopy, by Professor ... , , ...
(Date:12/8/2016)... , Dec. 8, 2016 Bodycad announced ... for improving the accuracy, reproducibility and speed for ... long and small bone orthopaedic applications. These patents ... creating personalized orthopaedic restorations based on each patient,s ... restorations, the company harnesses the world,s first suite ...
Breaking Medicine Technology: